DESOXIMETASONE
Clinical safety rating: safe
Animal studies have demonstrated safety
Desoximetasone is a potent corticosteroid that binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis. This leads to anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Desoximetasone is metabolized in the liver and skin via phase I (hydroxylation, reduction) and phase II (conjugation) pathways. Enzymes involved include CYP3A4 (minor) and glucuronosyltransferases. |
| Excretion | Primarily renal (urinary) as inactive metabolites, with less than 5% unchanged drug. Fecal excretion accounts for a minor fraction, primarily via bile. |
| Half-life | Terminal elimination half-life is approximately 1.5–2 hours. Due to its topical use, systemic half-life is less clinically relevant; however, prolonged use on large areas or under occlusion may lead to systemic accumulation. |
| Protein binding | Approximately 90–95% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Not well-characterized for topical use; intravenous studies in animals suggest a volume of distribution of approximately 1 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Systemic bioavailability is low (<5% in intact skin) but increases with skin barrier disruption, prolonged use, or large treatment areas. Oral bioavailability is negligible due to first-pass metabolism. |
| Onset of Action | Topical: Relief of inflammation and pruritus typically begins within a few hours of application, with maximum effect observed after 1–2 days of regular use. |
| Duration of Action | Topical: Duration of anti-inflammatory effect is approximately 6–8 hours, necessitating twice-daily application for sustained symptom control. Effect may last longer under occlusive dressing. |
| Molecular Weight | 376.47 |
Apply a thin film to affected skin areas twice daily.
| Dosage form | CREAM |
| Renal impairment | No specific dose adjustment required for renal impairment. |
| Liver impairment | No specific dose adjustment required for hepatic impairment. |
| Pediatric use | Apply a thin film to affected areas twice daily; use lowest potency and shortest duration possible due to increased systemic absorption. |
| Geriatric use | Use with caution; apply sparingly to limited areas due to increased risk of skin atrophy and systemic effects. |
| 1st trimester | Corticosteroids, including desoximetasone, are considered relatively safe in small amounts; however, large amounts or prolonged use should be avoided. Systemic absorption is minimal with topical application, but risk cannot be entirely ruled out. Use only if clearly needed. |
| 2nd trimester | Similar to first trimester; short-term use of small amounts is generally considered safe. Avoid prolonged use on large areas. |
| 3rd trimester | Use with caution; prolonged or high-dose use may cause fetal adrenal suppression. Generally avoid excessive use. |
Clinical note
No significant drug interactions Systemic absorption can occur with extensive use.
| Placental transfer | Topical corticosteroids cross the placenta to some extent. Systemic absorption is low, but fetal exposure depends on application area, duration, and skin integrity. Risk is minimal with short-term use on limited areas. |
| Breastfeeding |
■ FDA Black Box Warning
None.
| Common Effects | Skin atrophy |
| Serious Effects |
Hypersensitivity to desoximetasone or any component of the formulationUntreated bacterial, fungal, or viral skin lesions
| Precautions | Systemic absorption may cause reversible HPA axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., Prolonged use may produce atrophy of the skin, striae, and telangiectasias., Avoid use on infected lesions; if infection develops, discontinue and use appropriate antimicrobial therapy., Not for ophthalmic or oral use., Pediatric patients may be more susceptible to systemic toxicity due to higher skin surface-to-body weight ratio., Use with caution in patients with impaired hepatic function. |
| Food/Dietary | No known food interactions. Avoid excessive salt intake if hypokalemia occurs with prolonged high-dose use. |
Loading safety data…
| Topical corticosteroids are excreted in breast milk in small amounts, but systemic absorption is minimal with desoximetasone. Avoid application to the breast area to prevent infant ingestion. Short-term use is likely compatible; monitor infant for any signs of adrenal suppression. |
| Lactation Rating | L2 (Probably Compatible) |
| Teratogenic Risk | Desoximetasone is a topical corticosteroid. Systemic absorption is low but may increase with prolonged use over large areas, occlusive dressings, or damaged skin. Animal studies with corticosteroids have shown teratogenicity (cleft palate, intrauterine growth retardation). There are no adequate and well-controlled studies in pregnant women; however, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Risk cannot be ruled out, avoid use if possible. Second and third trimesters: Use with caution, especially with prolonged or widespread application, due to potential for fetal growth restriction and adrenal suppression. |
| Fetal Monitoring | If used during pregnancy, monitor for maternal adrenal suppression, especially with prolonged or widespread use. Fetal monitoring may include assessment of growth parameters (ultrasound) if prolonged high-dose therapy is necessary. Newborns exposed in utero should be monitored for adrenal insufficiency and growth retardation. |
| Fertility Effects | No human studies on fertility effects. Animal studies have not reported impairment of fertility. |
| Clinical Pearls | Desoximetasone is a high-potency topical corticosteroid (Class III) used for inflammatory and pruritic dermatoses. Limit application to small areas, avoid use on face, groin, or axillae. Monitor for local atrophy, striae, and systemic absorption, especially in pediatric patients. Do not use as monotherapy for rosacea, perioral dermatitis, or acne vulgaris. |
| Patient Advice | Apply a thin layer to affected skin only, avoiding healthy skin. · Do not cover with bandages or occlusive dressings unless directed by doctor. · Wash hands after application unless treating hands. · Do not use on face, underarms, or groin unless specifically instructed. · Report signs of skin thinning, increased redness, or irritation. · Do not use for longer than prescribed; continuous use can cause side effects. |